Showing 181 - 200 results of 52,679 for search '(( 6 0 decrease ) OR ( 50 ((we decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 0.67s Refine Results
  1. 181

    Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis by Eric N. Ouattara (6890174)

    Published 2019
    “…<i>Immediate ART</i> increased the 5-year HIV care budget from $801.9M to $812.6M compared to <i>ART<350/μL</i>.</p><p>Conclusions</p><p>In Côte d’Ivoire, immediate compared to later ART initiation will increase life expectancy, decrease HIV transmission, and be cost-effective over the long-term, with modest budget impact. …”
  2. 182
  3. 183
  4. 184

    Image_1_Electroencephalographic Evidence for Individual Neural Inertia in Mice That Decreases With Time.JPEG by Andrzej Z. Wasilczuk (11945885)

    Published 2022
    “…EEG was measured after induction of and emergence from isoflurane administered near the EC<sub>50</sub> dose for loss of righting in genetically inbred mice on a timescale that minimizes pharmacokinetic confounds. …”
  5. 185

    Decreased ISCs and increased goblet cells after intestinal specific loss of MLL1. by Neha Goveas (11790822)

    Published 2021
    “…<p><b>(A)</b> Kaplan-Meier survival curve. Tamoxifen was given by gavage for 6 days to mice with the genotype <i>Mll1</i><sup><i>FC/+; Vil-Cre-ERT2/+</i></sup> (n = 12) and <i>Mll1</i><sup><i>FC/FC; RC/+</i></sup> (n = 18). …”
  6. 186
  7. 187
  8. 188
  9. 189
  10. 190
  11. 191
  12. 192

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Structure–activity relationship study reveals that ethyl group substituent hydrazide-based ZBG and cap group with more substantial rigidity and larger volume increase the HDAC6 selectivity of designed compounds. Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. …”
  13. 193

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Structure–activity relationship study reveals that ethyl group substituent hydrazide-based ZBG and cap group with more substantial rigidity and larger volume increase the HDAC6 selectivity of designed compounds. Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. …”
  14. 194
  15. 195

    Contribution of direct emissions, seed, compost, other field operations, irrigation, mineral fertilisers, pesticides and transport of inputs to the climate change impact of conservation agriculture popcorn as a function of the percentage of impact allocated to compost: 7.2% (this study), 3.6% (50% decrease), 10.8% (50% increase), and 100% (original life cycle inventory from AGRIBALYSE; Avadi (2020)). by Maria Vittoria Guidoboni (15852669)

    Published 2023
    “…<p>Contribution of direct emissions, seed, compost, other field operations, irrigation, mineral fertilisers, pesticides and transport of inputs to the climate change impact of conservation agriculture popcorn as a function of the percentage of impact allocated to compost: 7.2% (this study), 3.6% (50% decrease), 10.8% (50% increase), and 100% (original life cycle inventory from AGRIBALYSE; Avadi (2020)).…”
  16. 196
  17. 197
  18. 198
  19. 199

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  20. 200

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”